4basebio UK
Societas
(the "Company")
Notice of Annual
General Meeting
Posting of Annual
Report and Financial Statements
4basebio UK Societas (AIM: 4BB), the specialist life
sciences group focused on exploiting intellectual property in the
field of gene therapies and vaccines, confirms that the Annual
Report and Accounts for the year ended 30 December 2020, and
the Notice of Annual General Meeting ("AGM") with accompanying
Form of Proxy has been posted to shareholders today.
These documents are also available, in electronic form, for
download on the Company's
website: https://www.4basebio.com/investors/.
The Company‘s AGM will be held at 09:00 a.m. on Wednesday,
30 June 2021 at the Company’s offices at 25 Norman Way, Over,
CB24 5QE. This will be followed by a presentation from the Company
through the Investor Meet Company platform on 1 July 2021 at 10am. Investors can sign up to Investor Meet
Company for free and register interest here:
https://www.investormeetcompany.com/4basebio-uk-societas/register-investor
The Company continues to monitor developments relating to the
outbreak of COVID-19, including the related public health guidance
and legislation issued by the UK Government as well as the “roadmap
out of lockdown” published on 22 February 2021. At present,
it is expected that it will be possible to hold a physical AGM and
to welcome the maximum number of shareholders we are able within
safety constraints and in accordance with government guidelines
that will apply at the time.
However, given the constantly evolving nature of the situation,
we want to ensure that we are able to adapt these arrangements
efficiently to respond to changes in circumstances. On this basis,
should the situation change such that we consider that it is no
longer possible for shareholders to attend the meeting, we will
adopt contingency plans and notify shareholders of the change via
an RNS announcement as early as is possible before the date of the
meeting. Such contingency plans are likely to result in the
holding of a virtual or hybrid meeting. Any updates to the
position will also be included on our website at
https://www.4basebio.com/investors/. Should we have to change the
arrangements in this way, it is likely that we will not be in a
position to accommodate shareholders beyond the minimum required to
hold a quorate meeting which will be achieved through the
attendance of employee shareholders.
Shareholders intending to attend the AGM, should this be
possible, are asked to register their intention as soon as
practicable (and the Company strongly encourages them to advise the
Company at least 48 hours in advance of the meeting) by emailing
the Company Secretary at david.roth@4basebio.com. Any such
communication shall not provide a guarantee that admittance to the
AGM will be permitted where to do so would be in breach of rules
governing public gatherings and/or the need to protect the health
and safety of those already in the meeting.
Given the uncertainty around whether shareholders will be able
to attend the AGM because of tighter restrictions due to a change
in the situation with the COVID-19 pandemic, we encourage all
shareholders to complete and return the accompanying Form of Proxy
appointing the Chair of the meeting as their proxy (or appoint the
Chair as their proxy through CREST). This will ensure that your
vote will be counted if ultimately you (or any other proxy you
might otherwise appoint) are not able to attend the meeting.
For further enquiries, please
contact:
4basebio UK
Societas |
+44 (0)12 2396
7943 |
Heikki Lanckriet,
CEO |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
+44 (0)20 7213
0880 |
Jo Turner / Sandy
Jamieson |
|
|
|
finnCap Ltd
(Broker) |
+44 (0)20 7220
0500 |
Geoff Nash/Richard
Chambers/Charlotte Sutcliffe |
|
|
|
Walbrook PR |
+44 (0)20
7933 8780 or 4basebio@walbrookpr.com |
Anna Dunphy / Paul McManus |
Mob: +44
(0)7876 741 001 / +44 (0)7980 541 893 |
|
|
|
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences group focused
on therapeutic DNA for gene therapies and DNA vaccines and
providing solutions for effective and safe delivery of these DNA
based products to patients. It is the intention of the Company to
become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological
use. The immediate objectives of 4bb are to validate and scale its
DNA synthesis and advance its collaborations to facilitate the
functional validation of its DNA based products and gene delivery
solutions.
The Company divested from 4basebio AG (“4bb AG”), a German
company listed on the Prime Standard segment of the Frankfurt Stock
Exchange, following the disposal by 4bb AG (then named Expedeon AG)
of its proteomics and immunology business to AIM-quoted Abcam plc
in January 2020 for €120million.
Following the disposal, 4bb AG retained its genomics business which
owned and licensed certain intellectual property including its
proprietary, patent-protected technology, TruePrime™. This is the
foundation for building the Company’s synthetic DNA manufacturing
business which 4bb AG transferred to the Company along with funding
to continue the Company’s development and investment.